Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial

for the ALTAIR Investigators

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Fingerprint Dive into the research topics of 'Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences